🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareNovo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026 Page 5

Novo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026

anders_CPH Thu, Mar 19, 2026 at 1:00 PM 22 replies 1,194 viewsPage 5 of 5
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Mar 26, 2026 at 10:16 PM#21

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

35 8JenMemphis, pat_auckland, Dr.GastroMayo and 32 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Mar 28, 2026 at 5:08 PM#22

A narrower follow-up, since the general answer is now clear:

How would you tell the difference between that and the alternative explanation?

36 9anna.melb_AU, mark_tokyo, hans_munich and 33 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Mar 30, 2026 at 11:59 AM#23
LabKate said:
If you are going to change something, change one thing and give it long enough to express itself.

Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.

Last edited: Mar 30, 2026 at 2:59 PM
37 10Dr.PulmRoch, maya_sedona, stefan_berlin and 34 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
MounjBrad
Member
278
890
Oct 2024
Kentucky
Apr 1, 2026 at 6:49 AM#24
LabKate said:
If you are going to change something, change one thing and give it long enough to express itself.

That is right, and it stops being right at the edges. The general case is well behaved; the interesting cases in this thread are all at the boundary where the general case breaks.

Ask again with the specifics and you will get a better answer than this one.

38 11pam_columbus, nick_SD_fit, ben_calgary and 35 others
Reply Quote Save Share Report
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Apr 3, 2026 at 1:38 AM#25
LabKate said:
If you are going to change something, change one thing and give it long enough to express itself.

That reframing is the part I needed. Sending this to two other people who asked me the same thing last week.

Last edited: Apr 3, 2026 at 2:38 AM
39 12mike_mealprep, NicoleRaleigh, james_edin and 36 others
Reply Quote Save Share Report
1345

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register